[Federal Register: October 1, 2010 (Volume 75, Number 190)]
[Notices]
[Page 60844-60846]
[DOCID:fr01oc10-114]

-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-62992; File No. SR-NASDAQ-2010-114]

Self-Regulatory Organizations; The NASDAQ Stock Market LLC;
Notice of Filing and Order Granting Accelerated Approval of Proposed
Rule Change To Prohibit Members From Voting Uninstructed Shares on
Certain Matters

September 24, 2010.
    Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934
(``Act''),\1\ and Rule 19b-4 thereunder,\2\ notice is hereby given that
on September 14, 2010, The NASDAQ Stock Market LLC (``Nasdaq'' or
``Exchange'') filed with the Securities and Exchange Commission
(``Commission'') the proposed rule change as described in Items I and
II below, which Items have been substantially prepared by Nasdaq. The
Commission is publishing this notice to solicit comments on the
proposed rule change from interested persons and is approving the
proposed rule change on an accelerated basis.
---------------------------------------------------------------------------

    \1\ 15 U.S.C. 78s(b)(1).
    \2\ 17 CFR 240.19b-4.
---------------------------------------------------------------------------

I. Self-Regulatory Organization's Statement of the Terms of the
Substance of the Proposed Rule Change

    Nasdaq proposes to modify Rule 2251 to prohibit members from voting
on the election of a member of the board of directors of an issuer
(except for a vote with respect to the uncontested election of a member
of the board of directors of any investment company registered under
the Investment Company Act of 1940), executive compensation, or any
other significant matter, as determined by the Commission, unless
instructed by the beneficial owner of the shares. The text of the
proposed rule change is below. Proposed new language is in italics;
proposed deletions are in brackets.\3\
---------------------------------------------------------------------------

    \3\ Changes are marked to the rule text that appears in the
electronic manual of Nasdaq found at http://
nasdaqomx.cchwallstreet.com.
---------------------------------------------------------------------------

2251. Forwarding of Proxy and Other Issuer-Related Materials
    (a)-(c) No change.
    (d) Notwithstanding the foregoing, a Nasdaq Member that is not the
beneficial owner of a security registered under Section 12 of the Act
is prohibited from granting a proxy to vote the security in connection
with a shareholder vote on the election of a member of the board of
directors of an issuer (except for a vote with respect to the
uncontested election of a member of the board of directors of any
investment company registered under the Investment Company Act of
1940), executive compensation, or any other significant matter, as
determined by the Commission, by rule, unless the beneficial owner of
the security has instructed the member to vote the proxy in accordance
with the voting instructions of the beneficial owner.
* * * * *

II. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

    In its filing with the Commission, Nasdaq included statements
concerning the purpose of and basis for the proposed rule change and
discussed any comments it received on the proposed rule change. The
text of these statements may be examined at the places specified in
Item III below. Nasdaq has prepared summaries, set forth in Sections A,
B, and C below, of the most significant aspects of such statements.

A. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

1. Purpose
    Section 957 of the Dodd-Frank Wall Street Reform and Consumer
Protection Act (the ``Dodd-Frank Act'') adopted new Section 6(b)(10) of
the Securities Exchange Act.\4\ This new provision requires all
national securities exchanges to adopt rules that prohibit their
members from voting on the election of a member of the board of
directors of an issuer (except for a vote with respect to the
uncontested election of a member of the board of directors of any
investment company registered under the Investment Company Act of
1940), executive compensation, or any other significant matter, as
determined by the Commission, unless the member receives voting
instructions from the beneficial owner of the shares.
---------------------------------------------------------------------------

    \4\ 15 U.S.C. 78f(b)(10).
---------------------------------------------------------------------------

    NASDAQ Rule 2251 governs when NASDAQ members may vote shares held
for customers by adopting the FINRA rule on this point. The FINRA rule,
in turn, prohibits members from voting any uninstructed shares, but
also permits the member to follow the rules of another SRO instead.\5\
In order to

assure compliance, in all cases, with newly adopted Section 6(b)(10),
NASDAQ proposes to modify Rule 2251 to provide that in no event could a
member vote uninstructed shares on the election of a member of the
board of directors of an issuer (except for a vote with respect to the
uncontested election of a member of the board of directors of any
investment company registered under the Investment Company Act of
1940), executive compensation, or any other significant matter, as
determined by the Commission, unless instructed by the beneficial owner
of the shares.
---------------------------------------------------------------------------

    \5\ The Commission notes that the FINRA rule, and by reference
Nasdaq's rule, only allows a member to follow the rules of another
SRO of which it is a member, provided that the records of the member
clearly indicate the procedure it is following. See FINRA Rule
2251(c)(2).
---------------------------------------------------------------------------

2. Statutory Basis
    Nasdaq believes that the proposed rule change is consistent with
the provisions of Section 6 of the Act,\6\ in general and with Section
6(b)(10) of the Act,\7\ in particular. Section 6(b)(10) requires that a
national securities exchange's rules must prohibit any member that is
not the beneficial owner of a security registered under Section 12 from
granting a proxy to vote the security in connection with a shareholder
vote on the election of a member of the board of directors of an issuer
(except for a vote with respect to the uncontested election of a member
of the board of directors of any investment company registered under
the Investment Company Act of 1940), executive compensation, or any
other significant matter, as determined by the Commission. The proposed
rule change will adopt the prohibition required by Section 6(b)(10).
---------------------------------------------------------------------------

    \6\ 15 U.S.C. 78f.
    \7\ 15 U.S.C. 78f(b)(10).
---------------------------------------------------------------------------

B. Self-Regulatory Organization's Statement on Burden on Competition

    Nasdaq does not believe that the proposed rule change will result
in any burden on competition that is not necessary or appropriate in
furtherance of the purposes of the Act, as amended.

C. Self-Regulatory Organization's Statement on Comments on the Proposed
Rule Change Received From Members, Participants, or Others

    Written comments were neither solicited nor received.

III. Solicitation of Comments

    Interested persons are invited to submit written data, views, and
arguments concerning the foregoing, including whether the proposed rule
change is consistent with the Act. Comments may be submitted by any of
the following methods:

Electronic Comments

     Use the Commission's Internet comment form (http://
www.sec.gov/rules/sro.shtml); or
     Send an e-mail to<EMAIL_ADDRESS>Please include
File Number SR-NASDAQ-2010-114 on the subject line.

Paper Comments

     Send paper comments in triplicate to Elizabeth M. Murphy,
Secretary, Securities and Exchange Commission, 100 F Street, NE.,
Washington, DC 20549-1090.

All submissions should refer to File Number SR-NASDAQ-2010-114. This
file number should be included on the subject line if e-mail is used.
To help the Commission process and review your comments more
efficiently, please use only one method. The Commission will post all
comments on the Commission's Internet Web site (http://www.sec.gov/
rules/sro.shtml). Copies of the submission, all subsequent amendments,
all written statements with respect to the proposed rule change that
are filed with the Commission, and all written communications relating
to the proposed rule change between the Commission and any person,
other than those that may be withheld from the public in accordance
with the provisions of 5 U.S.C. 552, will be available for Web site
viewing and printing in the Commission's Public Reference Room, 100 F
Street, NE., Washington, DC 20549, on official business days between
the hours of 10 a.m. and 3 p.m. Copies of such filing also will be
available for inspection and copying at the principal office of Nasdaq.
All comments received will be posted without change; the Commission
does not edit personal identifying information from submissions. You
should submit only information that you wish to make available
publicly. All submissions should refer to File Number SR-NASDAQ-2010-
114 and should be submitted on or before October 22, 2010.

IV. Commission's Findings and Order Granting Accelerated Approval of
the Proposed Rule Change

    In its filing, Nasdaq requested that the Commission approve the
proposal on an accelerated basis so that the Exchange could immediately
comply with the requirements imposed by the Dodd-Frank Act. After
careful consideration, the Commission finds that the proposed rule
change is consistent with the requirements of the Act and the rules and
regulations thereunder applicable to a national securities exchange.\8\
---------------------------------------------------------------------------

    \8\ In approving this rule change, the Commission notes that it
has considered the proposed rule's impact on efficiency,
competition, and capital formation. See 15 U.S.C. 78c(f).
---------------------------------------------------------------------------

    The Commission believes that the proposal is consistent with
Section 6(b)(10) \9\ of the Act, which requires that national
securities exchanges adopt rules prohibiting members that are not
beneficial holders of a security from voting uninstructed proxies with
respect to the election of a member of the board of directors of an
issuer (except for uncontested elections of directors for companies
registered under the Investment Company Act), executive compensation,
or any other significant matter, as determined by the Commission by
rule. The Commission also believes that the proposal is consistent with
Section 6(b)(5) \10\ of the Act, which provides, among other things,
that the rules of the Exchange must be designed to promote just and
equitable principles of trade, remove impediments to and perfect the
mechanism of a free and open market and a national market system, and,
in general, to protect investors and the public interest, and are not
designed to permit unfair discrimination between customers, issuers,
brokers, or dealers.
---------------------------------------------------------------------------

    \9\ 15 U.S.C. 78f(b)(10).
    \10\ 15 U.S.C. 78f(b)(5).
---------------------------------------------------------------------------

    The Commission believes that the proposal is consistent with
Section 6(b)(10) of the Act because it adopts revisions that comply
with that section. As noted in the accompanying Senate Report, Section
957, which adopts Section 6(b)(10), reflects the principle that ``final
vote tallies should reflect the wishes of the beneficial owners of the
stock and not be affected by the wishes of the broker that holds the
shares.'' \11\ The proposed rule change will make Nasdaq compliant with
the new requirements of Section 6(b)(10) by specifically prohibiting,
in Nasdaq's rule language, broker-dealers, who are not beneficial
owners of a security, from voting uninstructed shares in connection
with a shareholder vote on the election of a member of the board of
directors of an issuer (except for a vote with respect to the
uncontested election of a member of the board of directors of any
investment company registered under the Investment Company Act of
1940), executive compensation, or any other significant matter, as
determined by the Commission by rule, unless the member receives voting
instructions

from the beneficial owner of the shares.\12\
---------------------------------------------------------------------------

    \11\ See S. Rep. No. 111-176, at 136 (2010).
    \12\ The Commission has not, to date, adopted rules concerning
other significant matters where uninstructed broker votes should be
prohibited, although it may do so in the future. Should the
Commission adopt such rules, we would expect Nasdaq to adopt
coordinating rules promptly to comply with the statute.
---------------------------------------------------------------------------

    The Commission believes that the proposal is consistent with
Section 6(b)(5) of the Act because the proposal will further investor
protection and the public interest by assuring that shareholder votes
on the election of the board of directors of an issuer (except for a
vote with respect to the uncontested election of a member of the board
of directors of any investment company registered under the Investment
Company Act of 1940) and on executive compensation matters are made by
those with an economic interest in the company, rather than by a broker
that has no such economic interest, which should enhance corporate
governance and accountability to shareholders.\13\
---------------------------------------------------------------------------

    \13\ As the Commission stated in approving NYSE rules
prohibiting broker voting in the election of directors, having those
with an economic interest in the company vote the shares, rather
than the broker who has no such economic interest, furthers the goal
of enfranchising shareholders. See Securities Exchange Act Release
No. 60215 (July 1, 2009), 74 FR 33293 (July 10, 2009) (SR-NYSE-2006-
92).
---------------------------------------------------------------------------

    Based on the above, the Commission finds that the Nasdaq proposal
will further the purposes of Sections 6(b)(5) and 6(b)(10) of the Act
because it should enhance corporate accountability to shareholders
while also serving to fulfill the Congressional intent in adopting
Section 6(b)(10) of the Act.
    The Commission also finds good cause, pursuant to Section 19(b)(2)
of the Act,\14\ for approving the proposed rule change prior to the
30th day after the date of publication of notice in the Federal
Register. Section 6(b)(10) of the Act, enacted under Section 957 of the
Dodd-Frank Act, does not provide for a transition phase, and requires
rules of national securities exchanges to prohibit broker voting on the
election of a member of the board of directors of an issuer (except for
a vote with respect to the uncontested election of a member of the
board of directors of any investment company registered under the
Investment Company Act of 1940), executive compensation, or any other
significant matter, as determined by the Commission by rule. The
Commission believes that good cause exists to grant accelerated
approval to the Exchange's proposal, because it will conform Nasdaq
Rule 2251 to the requirements of Section 6(b)(10) of the Act.
---------------------------------------------------------------------------

    \14\ 15 U.S.C. 78s(b)(2).
---------------------------------------------------------------------------

V. Conclusion

    It is therefore ordered, pursuant to Section 19(b)(2) of the
Act,\15\ that the proposed rule change (SR-Nasdaq-2010-114) be, and it
hereby is, approved on an accelerated basis.
---------------------------------------------------------------------------

    \15\ 15 U.S.C. 78s(b)(2).

    For the Commission, by the Division of Trading and Markets,
pursuant to delegated authority.\16\
---------------------------------------------------------------------------

    \16\ 17 CFR 200.30-3(a)(12).
---------------------------------------------------------------------------

Florence E. Harmon,
Deputy Secretary.
[FR Doc. 2010-24606 Filed 9-30-10; 8:45 am]
BILLING CODE 8010-01-P


Isolates of Pseudomonas aeruginosa to Some Antibiotics and
Biocides,'' Journal of Applied Microbiology, 91:972-984, 2001.
71. Langsrud, S., G. Sundheim, and A. L. Holck, ``Cross-Resistance
to Antibiotics of Escherichia coli Adapted to Benzalkonium Chloride
or Exposed to Stress-Inducers,'' Journal of Applied Microbiology,
96:201-208, 2004.
72. Ledder, R. G., et al., ``Effects of Chronic Triclosan Exposure
Upon the Antimicrobial Susceptibility of 40 Ex-Situ Environmental
and Human Isolates,'' Journal of Applied Microbiology, 100:1132-
1140, 2006.
73. Loughlin, M. F., M. V. Jones, and P. A. Lambert, ``Pseudomonas
aeruginosa Cells Adapted to Benzalkonium Chloride Show Resistance to
Other Membrane-Active Agents But Not to Clinically Relevant
Antibiotics,'' Journal of Antimicrobial Chemotherapy, 49:631-639,
2002.
74. Randall, L. P., et al., ``Effect of Triclosan or a Phenolic Farm
Disinfectant on the Selection of Antibiotic-Resistant Salmonella
enterica,'' Journal of Antimicrobial Chemotherapy, 54:621-627, 2004.
75. Randall, L. P., et al., ``Prevalence of Multiple Antibiotic
Resistance in 443 Campylobacter spp. Isolated From Humans and
Animals,'' Journal of Antimicrobial Chemotherapy, 52:507-510, 2003.
76. Sanchez, P., E. Moreno, and J. L. Martinez, ``The Biocide
Triclosan Selects Stenotrophomonas maltophilia Mutants That
Overproduce the SmeDEF Multidrug Efflux Pump,'' Antimicrobial Agents
and Chemotherapy, 49:781-782, 2005.
77. Seaman, P. F., D. Ochs, and M. J. Day, ``Small-Colony Variants:
A Novel Mechanism for Triclosan Resistance in Methicillin-Resistant
Staphylococcus aureus,'' Journal of Antimicrobial Chemotherapy,
59:43-50, 2007.
78. Tkachenko, O., et al., ``A Triclosan-Ciprofloxacin Cross-
Resistant Mutant Strain of Staphylococcus aureus Displays an
Alteration in the Expression of Several Cell Membrane Structural and
Functional Genes,'' Research in Microbiology, 158:651-658, 2007.
79. Ciusa, M. L., et al., ``A Novel Resistance Mechanism to
Triclosan That Suggests Horizontal Gene Transfer and Demonstrates a
Potential Selective Pressure for Reduced Biocide Susceptibility in
Clinical Strains of Staphylococcus aureus,'' International Journal
of Antimicrobial Agents, 40:210-220, 2012.
80. Tandukar, M., et al., ``Long-Term Exposure to Benzalkonium
Chloride Disinfectants Results in Change of Microbial Community
Structure and Increased Antimicrobial Resistance,'' Environmental
Science and Technology, 47:9730-9738, 2013.
81. Zmantar, T., et al., ``Detection of Macrolide and Disinfectant
Resistance Genes in Clinical Staphylococcus aureus and Coagulase-
Negative staphylococci,'' BMC Research Notes, 4:453, 2011.
82. Ho, J. and J. Branley, ``Prevalence of Antiseptic Resistance
Genes qacA/B and Specific Sequence Types of Methicillin-Resistant
Staphylococcus aureus in the Era of Hand Hygiene,'' Journal of
Antimicrobial Chemotherapy, 67:1549-1550, 2012.
83. Johnson, J. G., et al., ``Frequency of Disinfectant Resistance
Genes in Pediatric Strains of Methicillin-Resistant Staphylococcus
aureus,'' Infection Control and Hospital Epidemiology, 34:1326-1327,
2013.
84. Batra, R., et al., ``Efficacy and Limitation of a Chlorhexidine-
Based Decolonization Strategy in Preventing Transmission of
Methicillin-Resistant Staphylococcus aureus in an Intensive Care
Unit,'' Clinical Infectious Diseases, 50:210-217, 2010.
85. Buffet-Bataillon, S., et al., ``Effect of Higher Minimum
Inhibitory Concentrations of Quaternary Ammonium Compounds in
Clinical E. coli Isolates on Antibiotic Susceptibilities and
Clinical Outcomes,'' Journal of Hospital Infection, 79:141-146,
2011.
86. Otter, J.A., et al., ``Selection for qacA Carriage in CC22, But
Not CC30, Methicillin-Resistant Staphylococcus

aureus Bloodstream Infection Isolates During a Successful
Institutional Infection Control Programme,'' Journal of
Antimicrobial Chemotherapy, 68:992-999, 2013.
87. Sangal, V., et al., ``Impacts of a Long-Term Programme of Active
Surveillance and Chlorhexidine Baths on the Clinical and Molecular
Epidemiology of Methicillin-Resistant Staphylococcus aureus (MRSA)
in an Intensive Care Unit in Scotland,'' International Journal of
Antimicrobial Agents, 40:323-331, 2012.
88. Interagency Task Force on Antimicrobial Resistance, ``A Public
Health Action Plan to Combat Antimicrobial Resistance. 2012
Update,'' 2012, available at http://www.cdc.gov/drugresistance/itfar/introduction_overview.html.
89. Ferrer, I. and E.T. Furlong, ``Identification of Alkyl
Dimethylbenzylammonium Surfactants in Water Samples by Solid-Phase
Extraction Followed by Ion Trap LC/MS and LC/MS/MS,'' Environmental
Science and Technology, 35:2583-2588, 2001.
90. Ferrer, I. and E.T. Furlong, ``Accelerated Solvent Extraction
Followed by On-Line Solid-Phase Extraction Coupled to Ion Trap LC/
MS/MS for Analysis of Benzalkonium Chlorides in Sediment Samples,''
Analytical Chemistry, 74:1275-1280, 2002.
91. Miller, T.R., et al., ``Fate of Triclosan and Evidence for
Reductive Dechlorination of Triclocarban in Estuarine Sediments,''
Environmental Science and Technology, 42:4570-4576, 2008.
92. ICH guidance for industry, ``S1B Testing for Carcinogenicity of
Pharmaceuticals,'' July 1997, available at http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm.
93. ICH guidance for industry, ``S7A Safety Pharmacology Studies for
Human Pharmaceuticals,'' July 2001, available at http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm.
94. ICH guideline, ``Detection of Toxicity to Reproduction for
Medicinal Products & Toxicity to Male Fertility S5(R2),'' November
2005, available at http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S5_R2/Step4/S5_R2__Guideline.pdf.
95. ICH guidance for industry, ``S1C(R2) Dose Selection for
Carcinogenicity Studies,'' (Revision 1), September 2008, available
at http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm.
96. ICH guidance for industry, ``M3(R2) Nonclinical Safety Studies
for the Conduct of Human Clinical Trials and Marketing Authorization
for Pharmaceuticals,'' (Revision 1), January 2010, available at
http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm.
97. FDA draft guidance for industry, ``Acne Vulgaris: Developing
Drugs for Treatment,'' September 2005, available at http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm.
98. FDA draft guidance for industry, ``Endocrine Disruption
Potential of Drugs: Nonclinical Evaluation,'' September 2013,
available at http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm.
99. FDA, ``Guideline for the Format and Content of the Human
Pharmacokinetics and Bioavailability Section of an Application,''
1987, available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072112.pdf.
100. Bashaw, E.D., et al., ``Maximal Usage Trial: An Overview of the
Design of Systemic Bioavailability Trial for Topical Dermatological
Products,'' Therapeutic Innovation and Regulatory Science, 2014.
101. Evans, V.A. and P. Orris, ``The Use of Alcohol-Based Hand
Sanitizers by Pregnant Health Care Workers,'' Journal of
Occupational and Environmental Medicine, 54:3, 2012.
102. Diamanti-Kandarakis, E., et al., ``Endocrine-Disrupting
Chemicals: An Endocrine Society Scientific Statement,'' Endocrine
Reviews, 30:293-342, 2009.
103. Sweetnam, P.M., et al., ``The Role of Receptor Binding in Drug
Discovery,'' Journal of Natural Products, 56:441-455, 1993.
104. ``Redbook 2000: IV.C.9.a: Guidelines for Reproduction
Studies,'' 2000, available at http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm2006826.htm.
105. EPA, ``Guidelines for Reproductive Toxicity Risk Assessment,''
October 1996, available at http://www2.epa.gov/sites/production/files/2014-11/documents/guidelines_repro_toxicity.pdf.
106. FDA guidance for industry, ``Nonclinical Safety Evaluation of
Pediatric Drug Products,'' available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079247.pdf.
107. Stoker, T.E., et al., ``Endocrine-Disrupting Chemicals:
Prepubertal Exposures and Effects on Sexual Maturation and Thyroid
Function in the Male Rat. A Focus on the EDSTAC Recommendations,''
Critical Reviews in Toxicology, 30:197-252, 2000.
108. McMurry, L.M., M. Oethinger, and S.B. Levy, ``Overexpression of
marA, soxS, or acrAB Produces Resistance to Triclosan in Laboratory
and Clinical Strains of Escherichia coli,'' FEMS Microbiology
Letters, 166:305-309, 1998.
109. Tabak, M., et al., ``Effect of Triclosan on Salmonella
typhimurium at Different Growth Stages and in Biofilms,'' FEMS
Microbiology Letters, 267:200-206, 2007.
110. Srinivasan, V.B., et al., ``Role of Novel Multidrug Efflux Pump
Involved in Drug Resistance in Klebsiella pneumoniae,'' PLoS One,
9:e96288, 2014.
111. Levy, S.B., ``Active Efflux, A Common Mechanism for Biocide and
Antibiotic Resistance,'' Journal of Applied Microbiology Symposium
Supplement, 92:65S-71S, 2002.
112. Russell, A.D., ``Do Biocides Select for Antibiotic
Resistance?,'' Journal of Pharmacy and Pharmacology, 52:227-233,
2000.
113. Yazdankhah, S.P., et al., ``Triclosan and Antimicrobial
Resistance in Bacteria: An Overview,'' Microbial Drug Resistance,
12:83-90, 2006.
114. Martinez, J.L., ``The Role of Natural Environments in the
Evolution of Resistance Traits in Pathogenic Bacteria,'' Proceedings
in Biological Science, 276:2521-2530, 2009.
115. Nguyen, M. and G. Vedantam, ``Mobile Genetic Elements in the
Genus Bacteroides, and Their Mechanism(s) of Dissemination,'' Mobile
Genetic Elements, 1:187-196, 2011.
116. Cha, J. and A.M. Cupples, ``Detection of the Antimicrobials
Triclocarban and Triclosan in Agricultural Soils Following Land
Application of Municipal Biosolids,'' Water Research, 43:2522-2530,
2009.
117. Kolpin, D.W., et al., ``Pharmaceuticals, Hormones, and Other
Organic Wastewater Contaminants in U.S. Streams, 1999-2000: A
National Reconnaissance,'' Environmental Science and Technology,
36:1202-1211, 2002.
118. Russell, A.D. and G. McDonnell, ``Concentration: A Major Factor
in Studying Biocidal Action,'' Journal of Hospital Infection, 44:1-
3, 2000.
119. Bevan, R.J., et al., ``An Assessment of Potential Cancer Risk
Following Occupational Exposure to Ethanol,'' Journal of Toxicology
and Environmental Health, Part B, 12:188-205, 2009.
120. Kirschner, M.H., et al., ``Transdermal Resorption of an
Ethanol- and 2-Propanol-Containing Skin Disinfectant,'' Langenbecks
Archives of Surgery, 394:151-157, 2009.
121. Brown, T.L., et al., ``Can Alcohol-Based Hand-Rub Solutions
Cause You to Lose Your Driver's License? Comparative Cutaneous
Absorption of Various Alcohols,'' Antimicrobial Agents and
Chemotherapy, 51:1107-1108, 2007.
122. Ahmed-Lecheheb, D., et al., ``Dermal and Pulmonary Absorption
of Ethanol From Alcohol-Based Hand Rub,'' Journal of Hospital
Infection, 81:31-35, 2012.
123. Miller, M.A., A. Rosin, and C.S. Crystal, ``Alcohol-Based Hand
Sanitizer: Can Frequent Use Cause an Elevated Blood Alcohol
Level?,'' American Journal of Infection Control, 34:150-151, 2006.
124. Bessonneau, V. and O. Thomas, ``Assessment of Exposure to
Alcohol Vapor From Alcohol-Based Hand Rubs,'' International Journal
of Environmental Research and Public Health, 9:868-879, 2012.
125. Beskitt, J.L. and J.D. Sun, ``In Vitro Skin Penetration
Characteristics of Ethanol in the Rabbit, Mouse, Rat, and Human,''
Journal of Toxicology--Cutaneous and Ocular Toxicology, 16:61-75,
1997.
126. Behl, C.R., et al., ``Hydration and Percutaneous Absorption: I.
Influence of Hydration on Alkanol Permeation

Through Hairless Mouse Skin,'' Journal of Investigative Dermatology,
75:346-352, 1980.
127. Durrheim, H., et al., ``Permeation of Hairless Mouse Skin I:
Experimental Methods and Comparison With Human Epidermal Permeation
by Alkanols,'' Journal of Pharmaceutical Sciences, 69:781-786, 1980.
128. Behl, C.R., et al., ``Hydration and Percutaneous Absorption
III: Influences of Stripping and Scalding on Hydration Alteration of
the Permeability of Hairless Mouse Skin to Water and n-Alkanols,''
Journal of Pharmaceutical Sciences, 71:229-234, 1982.
129. Flynn, G.L., H. Durrheim, and W.I. Higuchi, ``Permeation of
Hairless Mouse Skin II: Membrane Sectioning Techniques and Influence
on Alkanol Permeabilities,'' Journal of Pharmaceutical Sciences,
70:52-56, 1981.
130. National Toxicology Program, ``TR 478: Toxicology and
Carcinogenesis Studies of Diethanolamine in F344/N Rats and B6C3F1
Mice,'' 1999.
131. National Toxicology Program, ``NTP Toxicology and
Carcinogenesis Studies of Benzethonium Chloride (CAS No. 121-54-0)
in F344/N Rats and B6C3F1 Mice (Dermal Studies),'' National
Toxicology Program Technical Report Series, 438:1-220, 1995.
132. Stenback, F., ``The Tumorigenic Effect of Ethanol,'' Acta
Pathologica, Microbiologica, et Immunologica Scandinavica, 77:325-
326, 1969.
133. International Agency for Research on Cancer, ``IARC Monographs
on the Evaluation of Carcinogenic Risks to Humans. Volume 96,
Alcohol Consumption and Ethyl Carbamate,'' 2010, available at http://monographs.iarc.fr/ENG/Monographs/vol96/mono96.pdf.
134. National Toxicology Program, ``TR 510: Toxicology and
Carcinogenesis Studies of Urethane, Ethanol, and Urethane/Ethanol in
B6C3F1 Mice,'' 2004.
135. Watabiki, T., et al., ``Long-Term Ethanol Consumption in ICR
Mice Causes Mammary Tumor in Females and Liver Fibrosis in Males,''
Alcoholism, Clinical and Experimental Research, 24:117S-122S, 2000.
136. Soffritti, M.F., et al., ``Results of Long-Term Experimental
Studies on the Carcinogenicity of Methyl Alcohol and Ethyl Alcohol
in Rats,'' Annals of the New York Academy of Science, 982:46-69,
2003.
137. Baan, R., et al., ``Carcinogenicity of Alcoholic Beverages,''
Lancet, 8:292-293, 2007.
138. Centers for Disease Control and Prevention, ``Alcohol Use in
Pregnancy,'' Updated April 17, 2014, available at http://www.cdc.gov/ncbddd/fasd/alcohol-use.html.
139. Karl, P.I. and S.E. Fisher, ``Ethanol Alters Hormone Production
in Cultured Human Placental Trophoblasts,'' Alcoholism, Clinical and
Experimental Research, 17:816-821, 1993.
140. Santucci, L., T.J. Graham, and D.H. Van Thiel, ``Inhibition of
Testosterone Production by Rat Leydig Cells With Ethanol and
Acetaldehyde: Prevention of Ethanol Toxicity With 4-
methylpyrazole,'' Alcoholism, Clinical and Experimental Research,
7:135-139, 1983.
141. Salonen, I., P. Pakarinen, and I. Huhtaniemi, ``Effect of
Chronic Ethanol Diet on Expression of Gonadotropin Genes in the Male
Rat,'' Journal of Pharmacology and Experimental Therapeutics,
260:463-467, 1992.
142. Emanuele, N. and M.A. Emanuele, ``The Endocrine System: Alcohol
Alters Critical Hormonal Balance,'' Alcohol Health and Research
World, 21:53-64, 1997.
143. Heller, M. and L. Burd, ``Review of Ethanol Dispersion,
Distribution, and Elimination From the Fetal Compartment,'' Birth
Defects Research (Part A), 100:277-283, 2014.
144. Paintner, A., A.D. Williams, and L. Burd, ``Fetal Alcohol
Spectrum Disorders--Implications for Child Neurology, Part 1:
Prenatal Exposure and Dosimetry,'' Journal of Child Neurology,
27:258-263, 2012.
145. American College of Obstetricians and Gynecologists, ``Alcohol
and Pregnancy: Know the Facts,'' 2008, available at http://www.acog.org/About_ACOG/News_Room/News_Releases/2008/Alcohol_and_Pregnancy_Know_the_Facts.
146. Ali, Y., et al., ``Alcohols,'' Disinfection, Sterilization, and
Preservation, 5th ed., Philadelphia, PA: Lippincott Williams and
Wilkins, 229-254, 2001.
147. Kampf, G. and A. Kramer, ``Epidemiologic Background of Hand
Hygiene and Evaluation of the Most Important Agents for Scrubs and
Rubs,'' Clinical Microbiology Reviews, 17:863-893, 2004.
148. McDonnell, G.E., ``Alcohols,'' Antisepsis, Disinfection, and
Sterilization--Types, Action, and Resistance, ASM Press, Washington,
DC, 90-92, 2007.
149. Rutala, W.A., D.J. Weber, and Healthcare Infection Control
Practices Advisory Committee (HICPAC), ``Guideline for Disinfection
and Sterilization in Healthcare Facilities, 2008,'' 2008, available
at http://www.cdc.gov/hicpac/pdf/guidelines/disinfection_nov_2008.pdf.
150. G-Alegria, E., et al., ``High Tolerance of Wild Lactobacillus
plantarum and Oenococcus oeni Strains to Lyophilisation and Stress
Environmental Conditions of Acid pH and Ethanol,'' FEMS Microbiology
Letters, 230:53-61, 2004.
151. Cosmetic Ingredient Review, ``Final Report on the Safety
Assessment of Benzalkonium Chloride,'' Journal of the American
College of Toxicology, 8:589-625, 1989.
152. U.S. Environmental Protection Agency, ``Reregistration
Eligibility Decision for Alkyl Dimethyl Benzyl Ammonium Chloride
(ADBAC),'' 2006.
153. Comment No. FDA-1975-N-0012-0166.
154. Bore, E., et al., ``Adapted Tolerance to Benzalkonium Chloride
in Escherichia coli K-12 Studied by Transcriptome and Proteome
Analyses,'' Microbiology, 153:935-946, 2007.
155. Chuanchuen, R., et al., ``Susceptibilities to Antimicrobials
and Disinfectants in Salmonella Isolates Obtained From Poultry and
Swine in Thailand,'' Journal of Veterinary Medical Science, 70:595-
601, 2008.
156. Lear, J.C., et al., ``Chloroxylenol- and Triclosan-Tolerant
Bacteria From Industrial Sources--Susceptibility to Antibiotics and
Other Biocides,'' International Biodeterioration and Biodegradation,
57:51-56, 2006.
157. ``Annual Review of Cosmetic Ingredient Safety Assessments-2004/
2005,'' International Journal of Toxicology, 25 Suppl 2:1-89, 2006.
158. Scientific Committee on Cosmetic Products and Non-Food
Products, ``Opinion of the Scientific Committee on Cosmetic Products
and Non-Food Products (SCCNFP) Intended for Consumers Concerning
Benzethonium Chloride,'' 2002.
159. Scientific Committee on Cosmetic Products and Non-Food
Products, ``Opinion of the Scientific Committee on Cosmetic Products
and Non-Food Products (SCCNFP) Intended for Consumers Concerning
Benzethonium Chloride,'' 2003.
160. Comment No. FDA-1975-N-0012-0134.
161. Comment No. FDA-1975-N-0012-0171.
162. Comment No. FDA-1975-N-0012-0150.
163. Comment No. FDA-1975-N-0012-0186.
164. Lambert, R.J., ``Comparative Analysis of Antibiotic and
Antimicrobial Biocide Susceptibility Data in Clinical Isolates of
Methicillin-Sensitive Staphylococcus aureus, Methicillin-Resistant
Staphylococcus aureus and Pseudomonas aeruginosa Between 1989 and
2000,'' Journal of Applied Microbiology, 97:699-711, 2004.
165. Nakahara, H., et al., ``Benzethonium Chloride Resistance in
Pseudomonas aeruginosa Isolated From Clinical Lesions,''
Zentralblatt fur Bakteriologie, Mikrobiologie und Hygiene A,
257:409-413, 1984.
166. Jordan, B.J., et al., ``Human Volunteer Studies on Dettol
Bathing Product,'' Docket No. 1975N-0183H, 1973.
167. Jordan, B.J., J.D. Nichols, and M.J. Rance, ``Dettol Bathing
Product-Preliminary Volunteer Study,'' Docket No. 1975N-0183H, 1973.
168. Havler, M.E. and M.J. Rance, ``The Metabolism of p-Chloro-m-
xylenol (PCMX) in Sprague Dawley and Gunn Wistar Rats,'' Docket No.
1975N-0183H.
169. Sved, D.W., ``A Dermal Absorption Study With [14C]-Labeled PCMX
in Mice,'' Docket No. 1975N-0183H.
170. ``A 13-Week Dermal Toxicity Study in Mice,'' Comment No. FDA-
1975-N-0012-0242.
171. ``Teratology Study in Rats,'' Docket No. 1975N-0183.
172. Lear, J.C., et al., ``Chloroxylenol- and Triclosan-Tolerant
Bacteria From Industrial Sources,'' Journal of Industrial
Microbiology and Biotechnology, 29:238-242, 2002.

173. OTC Volume No. 020080.
174. National Toxicology Program, ``NTP: Toxicology and
Carcinogenesis Studies of 4-Hexylresorcinol in F3441N Rats and
B6C3F1 Mice, Technical Report Series, No. 330,'' 1988.
175. Robbin, B.H., ``Quantitative Studies on the Absorption and
Excretion of Hexylresorcinol and Heptylresorcinol Under Different
Conditions,'' Journal of Pharmacology and Experimental Therapy,
43:325-333, 1931.
176. Robbin, B.H., ``Quantitative Studies on the Absorption and
Excretion of Certain Resorcinols and Cresols in Dogs and Man,''
Journal of Pharmacology, 52:54-60, 1934.
177. McDonnell, G.E., ``Halogens and Halogen-Releasing Agents'' in
Antisepsis, Disinfection, and Sterilization--Types, Action, and
Resistance, ASM Press, Washington, DC, 102-111, 2007.
178. Agency for Toxic Substances and Disease Registry,
``Toxicological Profile for Iodine,'' April 2004, available at
http://www.atsdr.cdc.gov/toxprofiles/tp158.pdf.
179. International Programme on Chemical Safety, ``Iodine and
Inorganic Iodides: Human Health Aspects,'' Concise International
Chemical Assessment Document 72, 2009.
180. Bos, J.D. and M.M.H.M. Meinardi, ``The 500 Dalton Rule for the
Skin Penetration of Chemical Compounds and Drugs,'' Experimental
Dermatology, 9:165-169, 2000.
181. Brown, R.S., et al., ``Routine Skin Cleansing With Povidone-
Iodine Is Not a Common Cause of Transient Neonatal Hypothyroidism in
North America: A Prospective Controlled Study,'' Thyroid, 7:395-400,
1997.
182. Connolly, R.J. and J.J. Shepherd, ``The Effect of Preoperative
Surgical Scrubbing With Povidone Iodine on Urinary Iodine Levels,''
Australian and New Zealand Journal of Surgery, 42:94-95, 1972.
183. Nobukuni, K., et al., ``The Influence of Long-Term Treatment
With Povidone-Iodine on Thyroid Function,'' Dermatology, 195 Suppl
2:69-72, 1997.
184. Hays, M.T., ``Estimation of Total Body Iodine Content in Normal
Young Men,'' Thyroid, 11:671-675, 2001.
185. Vandilla, M.A. and M.J. Fulwyler, ``Thyroid Metabolism in
Children and Adults Using Very Small (Nanocurie) Doses of Iodine and
Iodine-131,'' Health Physics, 9:1325-1331, 1963.
186. Kanno, J., et al., ``Tumor-Promoting Effects of Both Iodine
Deficiency and Iodine Excess in the Rat Thyroid,'' Toxicologic
Pathology, 20:226-235, 1992.
187. Takegawa, K., et al., ``Induction of Squamous Cell Carcinomas
in the Salivary Glands of Rats by Potassium Iodide,'' Japanese
Journal of Cancer Research, 89:105-109, 1998.
188. Takegawa, K., et al., ``Large Amount of Vitamin A Has No Major
Effects on Thyroidal Hormone Synthesis in Two-Stage Rat Thyroid
Carcinogenesis Model Using N-bis(2-hydroxypropyl)nitrosamine and
Thiourea,'' Journal of Toxicological Sciences, 25:67-75, 2000.
189. Arrington, L.R., et al., ``Effects of Excess Dietary Iodine
Upon Rabbits, Hamsters, Rats and Swine,'' Journal of Nutrition,
87:394-398, 1965.
190. Coakley, J.C., et al., ``Transient Primary Hypothyroidism in
the Newborn: Experience of the Victorian Neonatal Thyroid Screening
Programme,'' Australian Paediatric Journal, 25:25-30, 1989.
191. Danziger, Y., A. Pertzelan, and M. Mimouni, ``Transient
Congenital Hypothyroidism After Topical Iodine in Pregnancy and
Lactation,'' Archives of Disease in Childhood, 62:295-296, 1987.
192. Delange, F., et al., ``Topical Iodine, Breastfeeding, and
Neonatal Hypothyroidism,'' Archives of Disease in Childhood, 63:106-
107, 1988.
193. Linder, N., et al., ``Topical Iodine-Containing Antiseptics and
Subclinical Hypothyroidism in Preterm Infants,'' Journal of
Pediatrics, 131:434-439, 1997.
194. Shoyinka, S.V., I.R. Obidike, and C.O. Ndumnego, ``Effect of
Iodine Supplementation on Thyroid and Testicular Morphology and
Function in Euthyroid Rats,'' Veterinary Research Communications,
32:635-645, 2008.
195. Smerdely, P., et al., ``Topical Iodine-Containing Antiseptics
and Neonatal Hypothyroidism in Very-Low-Birthweight Infants,''
Lancet, 2:661-664, 1989.
196. Bongers-Schokking, J.J., et al., ``Influence of Timing and Dose
of Thyroid Hormone Replacement on Development in Infants With
Congenital Hypothyroidism,'' Journal of Pediatrics, 136:292-297,
2000.
197. Calaciura, F., et al., ``Childhood IQ Measurements in Infants
With Transient Congenital Hypothyroidism,'' Clinical Endocrinology,
43:473-477, 1995.
198. Casteels, K., S. Punt, and J. Bramswig, ``Transient Neonatal
Hypothyroidism During Breastfeeding After Post-Natal Maternal
Topical Iodine Treatment,'' European Journal of Pediatrics, 159:716-
717, 2000.
199. Chanoine, J.P., et al., ``Increased Recall Rate at Screening
for Congenital Hypothyroidism in Breast Fed Infants Born to Iodine
Overloaded Mothers,'' Archives of Disease in Childhood, 63:1207-
1210, 1988.
200. Fisher, D.A., ``The Importance of Early Management in
Optimizing IQ in Infants With Congenital Hypothyroidism,'' Journal
of Pediatrics, 136:273-274, 2000.
201. Jackson, H.J. and R.M. Sutherland, ``Effect of Povidone-Iodine
on Neonatal Thyroid Function,'' Lancet, 2:992, 1981.
202. Jeng, M.J., et al., ``The Effect of Povidone-Iodine on Thyroid
Function of Neonates With Different Birth Sizes,'' Zhonghua Min Guo
Xiao Er Ke Yi Xue Hui Za Zhi, 39:371-375, 1998.
203. Koga, Y., et al., ``Effect on Neonatal Thyroid Function of
Povidone-Iodine Used on Mothers During Perinatal Period,'' Journal
of Obstetrics and Gynaecology (Tokyo, Japan), 21:581-585, 1995.
204. Lyen, K.R., et al., ``Transient Thyroid Suppression Associated
With Topically Applied Povidone-Iodine,'' American Journal of
Diseases of Children, 136:369-370, 1982.
205. Nobukuni, K. and S. Kawahara, ``Thyroid Function in Nurses: The
Influence of Povidone-Iodine Hand Washing and Gargling,''
Dermatology, 204 Suppl 1:99-102, 2002.
206. Perez-Lopez, F.R., ``Iodine and Thyroid Hormones During
Pregnancy and Postpartum,'' Gynecological Endocrinology, 23:414-428,
2007.
207. Turner, P., B. Saeed, and M.C. Kelsey, ``Dermal Absorption of
Isopropyl Alcohol From a Commercial Hand Rub: Implications for Its
Use in Hand Decontamination,'' Journal of Hospital Infection,
56:287-290, 2004.
208. Below, H., et al., ``Dermal and Pulmonary Absorption of Propan-
1-ol and Propan-2-ol From Hand Rubs,'' American Journal of Infection
Control, 40:250-257, 2012.
209. Puschel, K., ``Percutaneous Alcohol Intoxication,'' European
Journal of Pediatrics, 136:317-318, 1981.
210. Dhillon, S., ``Toxicology Updates-Isopropanol,'' Journal of
Applied Toxicology, 15:501-506, 1995.
211. International Programme on Chemical Safety, ``2-Propanol,''
1990, available at http://www.inchem.org/documents/ehc/ehc/ehc103.htm.
212. Boatman, R.J., et al., ``Dermal Absorption and Pharmacokinetics
of Isopropanol in the Male and Female F-344 Rat,'' Drug Metabolism
and Disposition, 26:197-202, 1998.
213. Martinez, T.T., et al., ``A Comparison of the Absorption and
Metabolism of Isopropyl Alcohol by Oral, Dermal and Inhalation
Routes,'' Veterinary and Human Toxicology, 28:233-236, 1986.
214. Slauter, R.W., et al., ``Disposition and Pharmacokinetics of
Isopropanol in F-344 Rats and B6C3F1 Mice,'' Fundamental and Applied
Toxicology, 23:407-420, 1994.
215. Kapp, R.W., Jr., et al., ``Isopropanol: Summary of TSCA Test
Rule Studies and Relevance to Hazard Identification,'' Regulatory
Toxicology and Pharmacology, 23:183-192, 1996.
216. WHO International Program on Chemical Safety Working Group,
``2-Propanol,'' Environmental Health Criteria, 103:132, 1990.
217. Slaughter, R.J., et al., ``Isopropanol Poisoning,'' Clinical
Toxicology, 52:470-478, 2014.
218. WHO International Agency for Research on Cancer, ``IARC
Monographs on the Evaluation of Carcinogenic Risks to Humans: Re-
Evaluation of Some Organic Chemicals, Hydrazine and Hydrogen
Peroxide,'' 71 (part 3):1027-1036, 1999, available at http://monographs.iarc.fr/ENG/Monographs/vol71/mono71.pdf.
219. Burleigh-Flayer, H., et al., ``Isopropanol Vapor Inhalation
Oncogenicity Study in Fischer 344 Rats and CD-1 Mice,'' Fundamental
and Applied Toxicology, 36:95-111, 1997.
220. Bates, H.K., et al., ``Developmental Neurotoxicity Evaluation
of Orally

Administered Isopropanol in Rats,'' Fundamental and Applied
Toxicology, 22:152-158, 1994.
221. Faber, W.D., K.L. Pavkov, and R. Gingell, ``Review of
Reproductive and Developmental Toxicity Studies With Isopropanol,''
Birth Defects Research Part B Developmental and Reproductive
Toxicology, 83:459-476, 2008.
222. Lehman, A.J., H. Schwerma, and E. Rickards, ``Isopropyl
Alcohol: Acquired Tolerance in Dogs, Rate of Disappearance From the
Blood Stream in Various Species, and Effects on Successive
Generation of Rats,'' Journal of Pharmacology and Experimental
Therapeutics, 85:61-69, 1945.
223. Nelson, B.K., et al., ``Teratogenicity of n-Propanol and
Isopropanol Administered at High Inhalation Concentrations to
Rats,'' Food and Chemical Toxicology, 26:247-254, 1988.
224. Tyl, R.W., et al., ``Developmental Toxicity Evaluation of
Isopropanol by Gavage in Rats and Rabbits,'' Fundamental and Applied
Toxicology, 22:139-151, 1994.
225. Bevan, C., et al., ``Two Generation Reproductive Toxicity Study
With Isopropanol in Rats,'' Journal of Applied Toxicology, 15:117-
123, 1995.
226. Allen, B., et al., ``Calculation of Benchmark Doses for
Reproductive and Developmental Toxicity Observed After Exposure to
Isopropanol,'' Regulatory Toxicology and Pharmacology, 28:38-44,
1998.
227. Gorkal, A.R. and A. Namasivayam, ``Effect of Isopropanol on Rat
Brain Monoamine Levels,'' Pharmacology and Toxicology, 65:390-392,
1989.
228. McEvoy, E.M., P.C. Wright, and M.T. Bustard, ``The Effect of
High Concentration Isopropanol on the Growth of a Solvent-Tolerant
Strain of Chlorella vulgaris,'' Enzyme and Microbial Technology,
35:140-146, 2004.
229. Geng, Y., et al., ``Biodegradation of Isopropanol by a Solvent-
Tolerant Paracoccus denitrificans Strain,'' Preparative Biochemistry
and Biotechnology, 45:491-499, 2015.
230. Bustard, M.T., et al., ``Biodegradation of High-Concentration
Isopropanol by a Solvent-Tolerant Thermophile, Bacillus pallidus,''
Extremophiles, 6:319-323, 2002.
231. Hiles, R.A. and C.G. Birch, ``The Absorption, Excretion, and
Biotransformation of 3,4,4'-Trichlorocarbanilide in Humans,'' Drug
Metabolism and Disposition, 6:177-183, 1978.
232. Howes, D. and J.G. Black, ``Percutaneous Absorption of
Triclocarban in Rat and Man,'' Toxicology, 6:67-76, 1976.
233. Scharpf, L.G., Jr., I.D. Hill, and H.I. Maibach, ``Percutaneous
Penetration and Disposition of Triclocarban in Man. Body
Showering,'' Archives of Environmental Health, 30:7-14, 1975.
234. Schebb, N.H., et al., ``Whole Blood Is the Sample Matrix of
Choice for Monitoring Systemic Triclocarban Levels,'' Chemosphere,
2012.
235. Schebb, N.H., et al., ``Investigation of Human Exposure to
Triclocarban After Showering and Preliminary Evaluation of Its
Biological Effects,'' Environmental Science and Technology, 45:3109-
3115, 2011.
236. Birch, C.G., et al., ``Biotransformation Products of 3,4,4'-
Trichlorocarbanilide in Rat, Monkey, and Man,'' Drug Metabolism and
Disposition, 6:169-176, 1978.
237. Gruenke, L.D., et al., ``A Selected Ion Monitoring GC/MS Assay
for 3,4,4'-Trichlorocarbanilide and Its Metabolites in Biological
Fluids,'' Journal of Analytical Toxicology, 11:75-80, 1987.
238. Hiles, R.A. and C.G. Birch, ``Nonlinear Metabolism and
Disposition of 3,4,4'-Trichlorocarbanilide in the Rat,'' Toxicology
and Applied Pharmacology, 46:323-337, 1978.
239. Hiles, R.A., et al., ``The Metabolism and Disposition of
3,4,4'-Trichlorocarbanilide in the Intact and Bile Duct-Cannulated
Adult and in the Newborn Rhesus Monkey (M. mulatta),'' Toxicology
and Applied Pharmacology, 46:593-608, 1978.
240. Warren, J.T., R. Allen, and D.E. Carter, ``Identification of
the Metabolites of Trichlorocarbanilide in the Rat,'' Drug
Metabolism and Disposition, 6:38-44, 1978.
241. Comment No. SUP41, Docket No. 1975N-0183.
242. Comment No. CP4, Docket No. 1975N-0183.
243. Beiswanger, B.B. and M.A. Tuohy, ``Analysis of Blood Plasma
Samples for Free Triclosan, Triclosan-Glucuronide, Triclosan Sulfate
and Total Triclosan From Subjects Using a Triclosan Dentrifice or a
Dentrifice, Bar Soap and Deodorant,'' Comment No. FDA-1975-N-0012-
0288.
244. Plezia, P., ``A Pilot Study for In Vivo Evaluation of the
Percutaneous Absorption of Triclosan,'' Comment No. FDA-1975-N-0012-
0196.
245. Queckenberg, C., et al., ``Absorption, Pharmacokinetics, and
Safety of Triclosan After Dermal Administration,'' Antimicrobial
Agents and Chemotherapy, 54:570-572, 2010.
246. Allmyr, M., et al., ``Human Exposure to Triclosan Via
Toothpaste Does Not Change CYP3A4 Activity or Plasma Concentrations
of Thyroid Hormones,'' Basic and Clinical Pharmacology and
Toxicology, 2009.
247. Lin, Y.J., ``Buccal Absorption of Triclosan Following Topical
Mouthrinse Application,'' American Journal of Dentistry, 13:215-217,
2000.
248. Moss, T., D. Howes, and F.M. Williams, ``Percutaneous
Penetration and Dermal Metabolism of Triclosan (2,4, 4'-trichloro-
2'-hydroxydiphenyl ether),'' Food and Chemical Toxicology, 38:361-
370, 2000.
249. Sandborgh-Englund, G., et al., ``Pharmacokinetics of Triclosan
Following Oral Ingestion in Humans,'' Journal of Toxicology and
Environmental Health, Part A, 69:1861-1873, 2006.
250. Tulp, M.T., et al., ``Metabolism of Chlorodiphenyl Ethers and
Irgasan DP 300,'' Xenobiotica, 9:65-77, 1979.
251. Van Dijk, A., ``14C-Triclosan: Absorption, Distribution,
Metabolism, and Elimination After Single/Repeated Oral and
Intravenous Administration to Hamsters,'' Comment No. FDA-1975-N-
0012-0288.
252. Van Dijk, A., ``14C-Triclosan: Absorption, Distribution,
Metabolism, and Elimination After Single/Repeated Oral and
Intravenous Administration to Mice,'' Comment No. FDA-1975-N-0012-
0288.
253. Wu, J.L., J. Liu, and Z. Cai, ``Determination of Triclosan
Metabolites by Using In-Source Fragmentation From High-Performance
Liquid Chromatography/Negative Atmospheric Pressure Chemical
Ionization Ion Trap Mass Spectrometry,'' Rapid Communications in
Mass Spectrometry, 24:1828-1834, 2010.
254. Burns, J.M., et al., ``14-Day Repeated Dose Dermal Study of
Triclosan in Rats (CHV 6718-102),'' Comment No. CP9, Docket No.
1975N-0183H, 1997.
255. Burns, J.M., et al., ``14-Day Repeated Dose Dermal Study of
Triclosan in Mice (CHV 6718-101),'' Comment No. CP9, Docket No.
1975N-0183H, 1997.
256. Burns, J.M., et al., ``14-Day Repeated Dose Dermal Study of
Triclosan in CD-1 Mice (CHV 2763-100),'' Comment No. CP9, Docket No.
1975N-0183H, 1997.
257. Trimmer, G.W., ``90-Day Subchronic Dermal Toxicity Study in the
Rat With Satellite Group With Irgasan DP 300 (MRD-92-399),'' Comment
No. C1, Docket No. 1975N-0183H, 1994.
258. Chambers, P.R., ``FAT 80'023/S Potential Tumorigenic and
Chronic Toxicity Effects in Prolonged Dietary Administration to
Hamsters,'' Comment No. PR5, Docket No. 1975N-0183H, 1999.
259. Chasseaud, L.F., et al., ``Toxicokinetics of FAT 80'023/S After
Prolonged Dietary Administration to Hamsters,'' Comment No. PR5,
Docket No. 1975N-0183H, 1999.
260. Comment No. FDA-1975-N-0012-0288.
261. Morseth, S.L., ``Two-Generation Reproduction Study in Rats FAT
80'023 (HLA Study No. 2386-100),'' Comment No. RPT7, Docket No.
1975N-0183, 1988.
262. James, M.O., et al., ``Triclosan Is a Potent Inhibitor of
Estradiol and Estrone Sulfonation in Sheep Placenta,'' Environment
International, 2009.
263. Cookson, B., ``Clinical Significance of Emergence of Bacterial
Antimicrobial Resistance in the Hospital Environment,'' Journal of
Applied Microbiology, 99:989-996, 2005.
264. MacIsaac, J.K., et al., ``Health Care Worker Exposures to the
Antibacterial Agent Triclosan,'' Journal of Occupational and
Environmental Medicine, 56:834-839, 2014.
265. Yueh, M.F., et al., ``The Commonly Used Antimicrobial Additive
Triclosan Is a Liver Tumor Promoter,'' Proceedings of the National
Academy of Sciences of the USA, 111:17200-17205, 2014.
266. Cherednichenko, G., et al., ``Triclosan Impairs Excitation-
Contraction Coupling

and Ca2+ Dynamics in Striated Muscle,'' Proceedings of the National
Academy of Sciences of the USA, 109:14158-14163, 2012.
267. Fritsch, E.B., et al., ``Triclosan Impairs Swimming Behavior
and Alters Expression of Excitation-Contraction Coupling Proteins in
Fathead Minnow (Pimephales promelas),'' Environmental Science and
Technology, 47:2008-2017, 2013.
268. Axelstad, M., et al., ``Triclosan Exposure Reduces Thyroxine
Levels in Pregnant and Lactating Rat Dams and in Directly Exposed
Offspring,'' Food and Chemical Toxicology, 59:534-540, 2013.
269. Lan, Z., et al., ``Triclosan Exhibits a Tendency to Accumulate
in the Epididymis and Shows Sperm Toxicity in Male Sprague-Dawley
Rats,'' Environmental Toxicology, 2013.
270. Fernando, D.M., et al., ``Triclosan Can Select for an AdeIJK-
Overexpressing Mutant of Acinetobacter baumannii ATCC 17978 That
Displays Reduced Susceptibility to Multiple Antibiotics,''
Antimicrobial Agents and Chemotherapy, 58:6424-6431, 2014.
271. Hernandez, A., et al., ``The Binding of Triclosan to SmeT, the
Repressor of the Multidrug Efflux Pump SmeDEF, Induces Antibiotic
Resistance in Stenotrophomonas maltophilia,'' PLoS Pathogens,
7:e1002103, 2011.
272. Mavri, A. and S.S. Mozina, ``Involvement of Efflux Mechanisms
in Biocide Resistance of Campylobacter jejuni and Campylobacter
coli,'' Journal of Medical Microbiology, 61:800-808, 2012.
273. Mavri, A. and S. Smole Mozina, ``Development of Antimicrobial
Resistance in Campylobacter jejuni and Campylobacter coli Adapted to
Biocides,'' International Journal of Food Microbiology, 160:304-312,
2013.
274. Srinivasan, V.B. and G. Rajamohan, ``KpnEF, A New Member of the
Klebsiella pneumoniae Cell Envelope Stress Response Regulon, Is an
SMR-Type Efflux Pump Involved in Broad-Spectrum Antimicrobial
Resistance,'' Antimicrobial Agents and Chemotherapy, 57:4449-4462,
2013.
275. McMurry, L.M., M. Oethinger, and S.B. Levy, ``Triclosan Targets
Lipid Synthesis,'' Nature, 394:531-532, 1998.
276. Zhang, Y.M., Y.J. Lu, and C.O. Rock, ``The Reductase Steps of
the Type II Fatty Acid Synthase as Antimicrobial Targets,'' Lipids,
39:1055-1060, 2004.
277. Saleh, S., et al., ``Triclosan--An Update,'' Letters in Applied
Microbiology, 52:87-95, 2011.
278. Nielsen, L.N., et al., ``Staphylococcus aureus But Not Listeria
monocytogenes Adapt to Triclosan and Adaptation Correlates With
Increased fabI Expression and agr Deficiency,'' BMC Microbiology,
13:177, 2013.
279. Zhu, L., et al., ``Triclosan Resistance of Pseudomonas
aeruginosa PAO1 Is Due to FabV, a Triclosan-Resistant Enoyl-acyl
Carrier Protein Reductase,'' Antimicrobial Agents and Chemotherapy,
54:689-698, 2010.
280. Zhu, L., et al., ``The Two Functional Enoyl-acyl Carrier
Protein Reductases of Enterococcus faecalis Do Not Mediate Triclosan
Resistance,'' MBio, 4:e00613-13, 2013.
281. Skovgaard, S., et al., ``Staphylococcus epidermidis Isolated in
1965 Are More Susceptible to Triclosan Than Current Isolates,'' PLoS
One, 8:e62197, 2013.
282. D'Arezzo, S., et al., ``High-level Tolerance to Triclosan May
Play a Role in Pseudomonas aeruginosa Antibiotic Resistance in
Immunocompromised Hosts: Evidence From Outbreak Investigation,'' BMC
Research Notes, 5:43, 2012.
283. Lanini, S., et al., ``Molecular Epidemiology of a Pseudomonas
aeruginosa Hospital Outbreak Driven by a Contaminated Disinfectant-
Soap Dispenser,'' PLoS One, 6:e17064, 2011.
284. Boyd, G.R., et al., ``Pharmaceuticals and Personal Care
Products (PPCPs) in Surface and Treated Waters of Louisiana, USA and
Ontario, Canada,'' Science and the Total Environment, 311:135-149,
2003.
285. Halden, R.U. and D.H. Paull, ``Co-Occurrence of Triclocarban
and Triclosan in U.S. Water Resources,'' Environmental Science and
Technology, 39:1420-1426, 2005.
286. Kinney, C.A., et al., ``Bioaccumulation of Pharmaceuticals and
Other Anthropogenic Waste Indicators in Earthworms From Agricultural
Soil Amended With Biosolid or Swine Manure,'' Environmental Science
and Technology, 42:1863-1870, 2008.
287. Singer, H., et al., ``Triclosan: Occurrence and Fate of a
Widely Used Biocide in the Aquatic Environment: Field Measurements
in Wastewater Treatment Plants, Surface Waters, and Lake
Sediments,'' Environmental Science and Technology, 36:4998-5004,
2002.
288. Ying, G.G., X.Y. Yu, and R.S. Kookana, ``Biological Degradation
of Triclocarban and Triclosan in a Soil Under Aerobic and Anaerobic
Conditions and Comparison With Environmental Fate Modelling,''
Environmental Pollution, 150:300-305, 2007.
289. Pycke, B.F.G., et al., ``Transformation Products and Human
Metabolites of Triclocarban and Triclosan in Sewage Sludge Across
the United States,'' Environmental Science and Technology, 48:7881-
7890, 2014.
290. Centers for Disease Control and Prevention, ``Alcohol and
Public Health. Frequently Asked Questions,'' 2014, available at
http://www.cdc.gov/alcohol/faqs.htm#standDrink.
291. Scientific Committee on Emerging and Newly Identified Health
Risks (SCENIHR), ``Research Strategy to Address the Knowledge Gaps
on the Antimicrobial Resistance Effects of Biocides,'' 2010,
available at http://ec.europa.eu/health/scientific_committees/emerging/docs/scenihr_o_028.pdf.
292. National Institute on Alcohol Abuse and Alcoholism, ``Fetal
Alcohol Exposure,'' July 2013, available at http://pubs.niaaa.nih.gov/publications/FASDFactsheet/FASDfact.htm.
293. Little, P.J., M.L. Adams, and T.J. Cicero, ``Effects of Alcohol
on the Hypothalamic-Pituitary-Gonadal Axis in the Developing Male
Rat,'' Journal of Pharmacology and Experimental Therapeutics,
263:1056-1061, 1992.

List of Subjects in 21 CFR Part 310

    Administrative practice and procedure, Drugs, Labeling, Medical
devices, Reporting and recordkeeping requirements.

    Therefore, under the Federal Food, Drug, and Cosmetic Act and under
authority delegated to the Commissioner of Food and Drugs, 21 CFR part
310, as proposed to be amended December 17, 2013, at 78 FR 76444, is
proposed to be further amended as follows:

PART 310--NEW DRUGS

0
1. The authority citation for 21 CFR part 310 continues to read as
follows:

    Authority: 21 U.S.C. 321, 331, 351, 352, 353, 355, 360b-360f,
360j, 361(a), 371, 374, 375, 379e, 379k-1; 42 U.S.C. 216, 241,
242(a), 262, 263b-263n.

0
2. Amend Sec.  310.545 as follows:
0
a. Add reserved paragraph (a)(27)(v);
0
b. Add paragraphs (a)(27)(vi) through (x);
0
c. In paragraph (d) introductory text, remove''(d)(39)'' and in its
place add ``(d)(42)''; and
0
d. Add paragraph (d)(42).
    The additions read as follows:

Sec.  310.545  Drug products containing certain active ingredients
offered over-the-counter (OTC) for certain uses.

    (a) * * *
    (27) * * *
    (v) [Reserved]
    (vi) Health care personnel hand wash drug products. Approved as of
[DATE 1 YEAR AFTER DATE OF PUBLICATION OF THE FINAL RULE IN THE FEDERAL
REGISTER].

Benzalkonium chloride
Benzethonium chloride
Chloroxylenol
Cloflucarban
Fluorosalan
Hexachlorophene
Hexylresorcinol
Iodine complex (ammonium ether sulfate and polyoxyethylene sorbitan
monolaurate)
Iodine complex (phosphate ester of alkylaryloxy polyethylene glycol)
Methylbenzethonium chloride
Nonylphenoxypoly (ethyleneoxy) ethanoliodine
Phenol
Poloxamer iodine complex
Povidone-iodine
Secondary amyltricresols

Sodium oxychlorosene
Tribromsalan
Triclocarban
Triclosan
Undecoylium chloride iodine complex

    (vii) Health care personnel hand rub drug products. Approved as of
[DATE 1 YEAR AFTER DATE OF PUBLICATION OF THE FINAL RULE IN THE FEDERAL
REGISTER].

Alcohol (ethanol and ethyl alcohol)
Benzalkonium chloride
Isopropyl alcohol

    (viii) Surgical hand scrub drug products. Approved as of [DATE 1
YEAR AFTER DATE OF PUBLICATION OF THE FINAL RULE IN THE FEDERAL
REGISTER].

Benzalkonium chloride
Benzethonium chloride
Chloroxylenol
Cloflucarban
Fluorosalan
Hexachlorophene
Hexylresorcinol
Iodine complex (ammonium ether sulfate and polyoxyethylene sorbitan
monolaurate)
Iodine complex (phosphate ester of alkylaryloxy polyethylene glycol)
Methylbenzethonium chloride
Nonylphenoxypoly (ethyleneoxy) ethanoliodine
Phenol
Poloxamer iodine complex
Povidone-iodine
Secondary amyltricresols
Sodium oxychlorosene
Tribromsalan
Triclocarban
Triclosan
Undecoylium chloride iodine complex

    (ix) Surgical hand rub drug products. Approved as of [DATE 1 YEAR
AFTER DATE OF PUBLICATION OF THE FINAL RULE IN THE FEDERAL REGISTER].

Alcohol (ethanol and ethyl alcohol)
Isopropyl alcohol

    (x) Patient preoperative skin preparation drug products. Approved
as of [DATE 1 YEAR AFTER DATE OF PUBLICATION OF THE FINAL RULE IN THE
FEDERAL REGISTER].

Alcohol (ethanol and ethyl alcohol)
Benzalkonium chloride
Benzethonium chloride
Chloroxylenol
Cloflucarban
Fluorosalan
Hexachlorophene
Hexylresorcinol
Iodine complex (phosphate ester of alkylaryloxy polyethylene glycol)
Iodine tincture
Iodine topical solution
Isopropyl alcohol
Mercufenol chloride
Methylbenzethonium chloride
Nonylphenoxypoly (ethyleneoxy) ethanoliodine
Phenol
Poloxamer iodine complex
Povidone-iodine
Secondary amyltricresols
Sodium oxychlorosene
Tribromsalan
Triclocarban
Triclosan
Triple dye
Undecoylium chloride iodine complex
Combination of calomel, oxyquinoline benzoate, triethanolamine, and
phenol derivative
Combination of mercufenol chloride and secondary amyltricresols in 50
percent alcohol
* * * * *
    (d) * * *
    (42) [DATE 1 YEAR AFTER DATE OF PUBLICATION OF THE FINAL RULE IN
THE FEDERAL REGISTER], for products subject to paragraphs (a)(27)(vi)
through (a)(27)(x) of this section.

    Dated: April 27, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015-10174 Filed 4-30-15; 8:45 am]
 BILLING CODE 4164-01-P


[Federal Register: October 31, 2008 (Volume 73, Number 212)]
[Notices]
[Page 64940-64941]
[DOCID:fr31oc08-61]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. ER09-62-000]

Erel Stillwater, LLC; Supplemental Notice That Initial Market-
Based Rate Filing Includes Request for Blanket Section 204
Authorization

October 23, 2008.
    This is a supplemental notice in the above-referenced proceeding of
Erel Stillwater, LLC's application for market-based rate authority,
with an accompanying rate schedule, noting that such application
includes a request for blanket authorization, under 18 CFR Part 34, of
future issuances of securities and assumptions of liability.
    Any person desiring to intervene or to protest should file with the
Federal Energy Regulatory Commission, 888 First Street, NE.,
Washington, DC 20426, in accordance with Rules 211 and 214 of the
Commission's Rules of Practice and Procedure (18 CFR 385.211 and
385.214). Anyone filing a motion to intervene or protest must serve a
copy of that document on the Applicant.
    Notice is hereby given that the deadline for filing protests with
regard to the applicant's request for blanket authorization, under 18
CFR Part 34, of future issuances of securities and assumptions of
liability, is November 24, 2008.
    The Commission encourages electronic submission of protests and
interventions in lieu of paper, using the FERC Online links at http://
www.ferc.gov. To facilitate electronic service, persons with Internet
access who will eFile a document and/or be listed as a contact for an
intervenor must create and validate an eRegistration account using the
eRegistration link. Select the eFiling link to log on and submit the
intervention or protests.
    Persons unable to file electronically should submit an original and
14 copies of the intervention or protest to the Federal Energy
Regulatory Commission, 888 First St., NE., Washington, DC 20426.
    The filings in the above-referenced proceeding are accessible in
the Commission's eLibrary system by

clicking on the appropriate link in the above list. They are also
available for review in the Commission's Public Reference Room in
Washington, DC. There is an eSubscription link on the Web site that
enables subscribers to receive e-mail notification when a document is
added to a subscribed dockets(s). For assistance with any FERC Online
service, please e-mail<EMAIL_ADDRESS>or call (866) 208-
3676 (toll free). For TTY, call<PHONE_NUMBER>.

Kimberly D. Bose,
Secretary.
[FR Doc. E8-25975 Filed 10-30-08; 8:45 am]

BILLING CODE 6717-01-P


[Federal Register: December 16, 2005 (Volume 70, Number 241)]
[Notices]
[Page 74850]
[DOCID:fr16de05-102]

=======================================================================
-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

Sunshine Act Meeting

    Notice is hereby given, pursuant to the provisions of the
Government in the Sunshine Act, Public Law 94-409, that the Securities
and Exchange Commission will hold the following meeting during the week
of December 19, 2005:
    A Closed Meeting will be held on Tuesday, December 20, 2005 at 2
p.m.
    Commissioners, Counsel to the Commissioners, the Secretary to the
Commission, and recording secretaries will attend the Closed Meeting.
Certain staff members who have an interest in the matters may also be
present.
    The General Counsel of the Commission, or his designee, has
certified that, in his opinion, one or more of the exemptions set forth
in 5 U.S.C. 552b(c), (3), (5), (7), (8), (9)(B), and (10) and 17 CFR
200.402(a), (3), (5), (7), (8), 9(ii) and (10) permit consideration of
the scheduled matters at the Closed Meeting.
    Commissioner Campos, as duty officer, voted to consider the items
listed for the closed meeting in closed session.
    The subject matter of the Closed Meeting scheduled for Tuesday,
December, 20, 2005 will be:

Formal orders of investigations;
Institution and settlement of injunctive actions;
Institution and settlement of administrative proceedings of an
enforcement nature; and
Post-argument discussion.

    At times, changes in Commission priorities require alterations in
the scheduling of meeting items.
    For further information and to ascertain what, if any, matters have
been added, deleted or postponed, please contact: The Office of the
Secretary at<PHONE_NUMBER>.

    Dated: December 13, 2005.
Jonathan G. Katz,
Secretary.
[FR Doc. 05-24186 Filed 12-14-05; 11:09 am]

BILLING CODE 8010-01-P


[Federal Register Volume 82, Number 33 (Tuesday, February 21, 2017)]
[Notices]
[Pages 11213-11214]
[FR Doc No: 2017-03325]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Project No. 190-105]

Moon Lake Electric Association, Inc.; Notice of Application
Tendered for Filing With the Commission and Soliciting Additional Study
Requests and Establishing Procedural Schedule for Relicensing and a
Deadline for Submission of Final Amendments

    Take notice that the following hydroelectric application has been
filed with the Commission and is available for public inspection.
    a. Type of Application: Minor, new license.
    b. Project No.: P-190-105.
    c. Date Filed: January 31, 2017.
    d. Applicant: Moon Lake Electric Association, Inc.
    e. Name of Project: Uintah Hydroelectric Project.
    f. Location: The project is located near the Town of Neola,
Duchesne County, Utah and diverts water from primarily the Uintah River
as well as Big Springs Creek and Pole Creek. The project is located
almost entirely on federal lands managed by Ashley National Forest and
Ute Indian Reservation.
    g. Filed Pursuant to: Federal Power Act 16 U.S.C. 791(a)-825(r).
    h. Applicant Contact: M. Jared Griffiths, Engineering Manager, Moon
Lake Electric Association, Inc., 800 West U.S. Hwy 40, Roosevelt, Utah
84066.
    i. FERC Contact: Quinn Emmering,<PHONE_NUMBER>,
<EMAIL_ADDRESS>    j. Cooperating Agencies: Federal, state, local, and tribal agencies
with jurisdiction and/or special expertise with respect to
environmental issues that wish to cooperate in the preparation of the
environmental document should follow the instructions for filing such
requests described in item l below. Cooperating agencies should note
the Commission's policy that agencies that cooperate in the preparation
of the environmental document cannot also intervene. See, 94 FERC
61,076 (2001).
    k. Pursuant to section 4.32(b)(7) of 18 CFR of the Commission's
regulations, if any resource agency, Indian Tribe, or person believes
that an additional scientific study should be conducted in order to
form an adequate factual basis for a complete analysis of the
application on its merit, the resource agency, Indian Tribe, or person
must file a request for a study with the Commission not later than 60
days from the date of filing of the application, and serve a copy of
the request on the applicant.
    l. Deadline for filing additional study requests and requests for
cooperating agency status: April 3, 2017.
    The Commission strongly encourages electronic filing. Please file
additional study requests and requests for cooperating agency status
using the Commission's eFiling system at http://www.ferc.gov/docs-filing/efiling.asp. For assistance, please contact FERC Online Support
at<EMAIL_ADDRESS>(866) 208-3676 (toll free), or (202)
502-8659 (TTY). In lieu of electronic filing, please send a paper copy
to: Secretary, Federal Energy Regulatory Commission, 888 First Street
NE., Washington, DC 20426. The first page of any filing should include
docket number P-190-105.
    m. The application is not ready for environmental analysis at this
time.
    n. The Uintah Hydroelectric project operates as a run-of-river
facility delivering water to the project facilities from three sources:
the Uintah River, Big Springs Creek, and Pole Creek. The existing
project facilities include: (1) An 8-foot-wide, 4-foot-deep, 1,100-
foot-long canal that delivers water from Big Springs Creek; (2) a
concrete diversion structure on the Big Springs Creek canal which
conveys flow through a 916-foot-long, 28-inch diameter, steel pipeline
that connects to the point of diversion on the Uintah River; (3) an 80-
foot-long, 4-foot-wide, 3-foot-high overflow-type concrete diversion
structure with a 10-foot-high, 6.5-foot-wide steel slide gate on the
Uintah River; (4) a 16-foot-wide, 8-foot-deep, 25,614-foot-long, main
supply canal which conveys water from Big Springs Creek and the Uintah
River; (5) a stop-log diversion structure which diverts water from Pole
Creek; (6) a 6-foot-wide, 4-foot-deep, 6,200-foot-long supply canal
which collects water from the Pole Creek diversion; (7) an 86-inch-
wide, 80-inch-long, 43-inch-high transition bay and a 140-foot-long,
14-inch diameter steel penstock collects water from the Pole Creek
supply canal; (8) a 23-foot by 13-foot concrete forebay structure
containing trashracks, an overflow channel, and a headgate that is
located at the termination of the main supply canal and the Pole Creek
penstock; (9) a single 5,238-foot-long, 36-inch diameter polyurethane
and steel penstock which delivers water to a concrete powerhouse with
two Pelton turbines driving two 600-kilowatt generators; (10) a 600-
foot-long tailrace; (11) a 4.75-mile-long, 24.9-kilovolt single wood
pole distribution line; and (12) appurtenant facilities. The estimated
average annual generation is about 6,073 megawatt-hours. The licensee
proposes to modify the project boundary to account for an update to the
project transmission line that reduced its total length from 8.5 miles
to 4.75 miles. The licensee proposes no operational changes or new
project facilities at this time.
    o. A copy of the application is available for review at the
Commission in the Public Reference Room or may be viewed on the
Commission's Web site at http://www.ferc.gov using the ``eLibrary''
link. Enter the docket number excluding the last three digits in the
docket number field to access the document. For assistance, contact
FERC Online Support. A copy is also available for inspection and
reproduction at the address in item h above.
    You may also register online at http://www.ferc.gov/docs-filing/esubscription.asp to be notified via email of new filings and issuances
related to this or other pending projects. For assistance, contact FERC
Online Support.
    q. Procedural schedule and final amendments: The application will
be processed according to the following preliminary Hydro Licensing
Schedule. Revisions to the schedule will be made as appropriate.

Issue Notice of Acceptance--April 2017
Request Additional Information (if necessary)--April 2017
Issue Acceptance Letter--July 2017
Issue Scoping Document 1 for comments--August 2017
Request Additional Information (if necessary)--October 2017
Issue Scoping Document 2--November 2017
Issue notice of ready for environmental analysis--November 2017
Commission issues EA, draft EA, or draft EIS--May 2018

Comments on EA or draft EA or draft EIS--June 2018
Commission issues final EA of final EIS--August 2018

    Final amendments to the application must be filed with the
Commission no later than 30 days from the issuance date of the notice
of ready for environmental analysis.

    Dated: February 14, 2017.
Kimberly D. Bose,
 Secretary.
[FR Doc. 2017-03325 Filed 2-17-17; 8:45 am]
 BILLING CODE 6717-01-P


[Federal Register Volume 87, Number 64 (Monday, April 4, 2022)]
[Rules and Regulations]
[Pages 19390-19392]
[FR Doc No: 2022-06937]

=======================================================================
-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 52

[EPA-R07-OAR-2022-0075; FRL-9428-02-R7]

Air Plan Approval; Kansas; 2015 Ozone NAAQS Interstate Transport
Requirements

AGENCY: Environmental Protection Agency (EPA).

ACTION: Final rule.

-----------------------------------------------------------------------

SUMMARY: The Environmental Protection Agency (EPA) is approving a State
Implementation Plan (SIP) revision submitted by the State of Kansas as
meeting the Clean Air Act (CAA) requirement that each State's SIP
contain adequate provisions to prohibit emissions that will
significantly contribute to nonattainment or interfere with maintenance
of the 2015 8-hour ozone national ambient air quality standards (NAAQS)
in any other state. This action is being taken in accordance with the
CAA.

DATES: This final rule is effective on May 4, 2022.

ADDRESSES: The EPA has established a docket for this action under
Docket ID No. EPA-R07-OAR-2022-0075. All documents in the docket are
listed on the https://www.regulations.gov website. Although listed in
the index, some information is not publicly available, i.e., CBI or
other information whose disclosure is restricted by statute. Certain
other material, such as copyrighted material, is not placed on the
internet and will be publicly available only in hard copy form.
Publicly available docket materials are available through https://www.regulations.gov or please contact the person identified in the FOR
FURTHER INFORMATION CONTACT section for additional information.

FOR FURTHER INFORMATION CONTACT: William Stone, Environmental
Protection Agency, Region 7 Office, Air Quality Planning Branch, 11201
Renner Boulevard, Lenexa, Kansas 66219; telephone number: (913) 551-
7714; email address: [email protected].

SUPPLEMENTARY INFORMATION: Throughout this document ``we,'' ``us,'' and
``our'' refer to EPA.

Table of Contents

I. Background and Purpose
II. Final Action
III. Statutory and Executive Order Reviews

I. Background and Purpose

    On February 7, 2022, EPA published a Notice of Proposed Rulemaking
(NPRM) for the State of Kansas. See 87 FR 7071. The NPRM proposed
approval of a Kansas SIP revision that addresses the CAA requirement
prohibiting emissions from the state that significantly contribute to
nonattainment or interfere with maintenance of the 2015 8-hour ozone
NAAQS in other states. See CAA section 110(a)(2)(D)(i)(I) (the ``good
neighbor provision''). The SIP revision was submitted to EPA by Kansas
on September 27, 2018. The rationale for EPA's proposed action is given
in the NPRM and will not be repeated here. In section IV. of the NPRM,
EPA erroneously stated that Kansas submitted the Kansas submission on
October 1, 2018. The submission was received on September 27, 2018.
    EPA received one public comment in support of the proposed action.

II. Final Action

    EPA is approving a Kansas SIP revision, which was submitted on
September 27, 2018. This submission is approved as meeting CAA section
110(a)(2)(D)(i)(I) requirements that Kansas's SIP includes adequate
provisions prohibiting any source or other type of emissions activity
within the state from emitting any air pollutant in amounts that will
contribute significantly to nonattainment or interfere with maintenance
of the 2015 ozone NAAQS in any other state.

III. Statutory and Executive Order Reviews

    Under the Clean Air Act (CAA), the Administrator is required to
approve a SIP submission that complies with the provisions of the Act
and applicable Federal regulations. 42 U.S.C. 7410(k); 40 CFR 52.02(a).
Thus, in reviewing SIP submissions, EPA's role is to approve state
choices, provided that they meet the criteria of the CAA. Accordingly,
this action merely approves state law as meeting Federal requirements
and does not impose additional requirements beyond those imposed by
state law. For that reason, this action:
     Is not a significant regulatory action subject to review
by the Office of Management and Budget under Executive Orders 12866 (58
FR 51735, October 4, 1993) and 13563 (76 FR 3821, January 21, 2011);
     Does not impose an information collection burden under the
provisions of the Paperwork Reduction Act (44 U.S.C. 3501 et seq.);
     Is certified as not having a significant economic impact
on a substantial number of small entities under the Regulatory
Flexibility Act (5 U.S.C. 601 et seq.);
     Does not contain any unfunded mandate or significantly or
uniquely affect small governments, as described in the Unfunded
Mandates Reform Act of 1995 (Pub. L. 104-4);
     Does not have federalism implications as specified in
Executive Order 13132 (64 FR 43255, August 10, 1999);
     Is not an economically significant regulatory action based
on health or safety risks subject to Executive Order 13045 (62 FR
19885, April 23, 1997);
     Is not a significant regulatory action subject to
Executive Order 13211 (66 FR 28355, May 22, 2001);
     Is not subject to requirements of the National Technology
Transfer and Advancement Act (NTTA) because this rulemaking does not
involve technical standards; and
     Does not provide EPA with the discretionary authority to
address, as appropriate, disproportionate human health or environmental
effects, using practicable and legally permissible methods, under
Executive Order 12898 (59 FR 7629, February 16, 1994).
    In addition, the SIP is not approved to apply on any Indian
reservation land or in any other area where the EPA or an Indian tribe
has demonstrated that a tribe has jurisdiction. In those areas of
Indian country, the rule does not have tribal implications and will not
impose substantial direct costs on tribal governments or preempt tribal
law as specified by Executive Order 13175 (65 FR 67249, November 9,
2000).
    The Congressional Review Act, 5 U.S.C. 801 et seq., as added by the
Small Business Regulatory Enforcement Fairness Act of 1996, generally
provides that before a rule may take effect, the agency promulgating
the rule must submit a rule report, which includes a copy of the rule,
to each House of the Congress and to the Comptroller General of the
United States. EPA will submit a report containing this action and
other required information to the U.S. Senate, the U.S. House of
Representatives, and the Comptroller General of the United States prior
to publication of the rule in the Federal Register. A major rule cannot
take effect until 60 days after it is published in the Federal
Register. This action is not a ``major rule'' as defined by 5 U.S.C.
804(2).
    Under section 307(b)(1) of the CAA, petitions for judicial review
of this action must be filed in the United States Court of Appeals for
the appropriate circuit by June 3, 2022. Filing a petition for
reconsideration by the Administrator of this final rule does not affect
the finality of this action for the purposes of judicial review nor
does it extend the time within which a petition for judicial review may
be filed, and shall not postpone the effectiveness of such rule or
action. This action may not be challenged later in proceedings to
enforce its requirements (see section 307(b)(2)).

List of Subjects in 40 CFR Part 52

    Environmental protection, Air pollution control, Incorporation by
reference, Intergovernmental relations, Nitrogen dioxide, Ozone,
Reporting and recordkeeping requirements, Volatile organic compounds.

    Dated: March 28, 2022.
Meghan A. McCollister,
Regional Administrator, Region 7.

    For the reasons stated in the preamble, the EPA amends 40 CFR part
52 as set forth below:

PART 52--APPROVAL AND PROMULGATION OF IMPLEMENTATION PLANS

0
1. The authority citation for part 52 continues to read as follows:

    Authority:  42 U.S.C. 7401 et seq.

Subpart R--Kansas

0
2. In Sec.  52.870, the table in paragraph (e) is amended by adding the
entry ``(47)'' in numerical order to read as follows:

Sec.  52.870   Identification of plan.

* * * * *
    (e) * * *

                                  EPA-Approved Kansas Nonregulatory Provisions
----------------------------------------------------------------------------------------------------------------
                                   Applicable          State
 Name of non regulatory SIP       geographic or      submittal          EPA approval date          Explanation
          provision            nonattainment area       date
----------------------------------------------------------------------------------------------------------------

                                                  * * * * * * *
(47) Transport SIP for the    Statewide...........    9/27/2018  4/4/2022, [insert Federal       [EPA-R07-OAR-20
 2015 Ozone Standard.                                             Register citation].             22-0075; FRL-
                                                                                9428-02-R7].
                                                                                This transport
                                                                                SIP shows that
                                                                                Kansas does
                                                                                not
                                                                                significantly
                                                                                contribute to
                                                                                ozone
                                                                                nonattainment
                                                                                or maintenance
                                                                                in any other
                                                                                state. This
                                                                                submittal is
                                                                                approved as
                                                                                meeting the
                                                                                requirements
                                                                                of Clean Air
                                                                                Act section
                                                                                110(a)(2)(D)(i
                                                                                )(I).
----------------------------------------------------------------------------------------------------------------

[FR Doc. 2022-06937 Filed 4-1-22; 8:45 am]
BILLING CODE 6560-50-P


[Federal Register: September 15, 2008 (Volume 73, Number 179)]
[Notices]
[Page 53246-53249]
[DOCID:fr15se08-68]

-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

[FRL-OW-FRL-8715-3]

Revision of National Recommended Water Quality Criteria for
Acrolein and Phenol

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice of availability of updated draft criteria and request
for scientific views.

-----------------------------------------------------------------------

SUMMARY: Pursuant to section 304(a) of the Clean Water Act (CWA), the
Environmental Protection Agency (EPA) is announcing the revision and
availability of draft updated national recommended water quality
criteria for the protection of human health for acrolein and phenol.
The draft criteria are partial updates based on EPA's Methodology for
Deriving Ambient Water Quality Criteria for the Protection of Human
Health (2000), EPA-822-B-00-004 (2000 Human Health Methodology) and
will supersede previously published criteria when final. EPA's
recommended section 304(a) water quality criteria provide guidance to
States and authorized Tribes in adopting water quality standards for
protecting human health and provide guidance to EPA for promulgating
Federal regulations under CWA section 303(c), when such action is
necessary.

DATES: Scientific views must be received on or before October 30, 2008.

Comments postmarked after this date may not be considered.

ADDRESSES: Submit your scientific views, identified by Docket ID No.
EPA-HQ-OW-2008-0553, by one of the following methods:
     http://www.regulations.gov: Follow the on-line
instructions for submitting comments.
     E-mail<EMAIL_ADDRESS>     Mail: U.S. Environmental Protection Agency; EPA Docket
Center (EPA/DC) Water Docket, MC 2822T; 1200 Pennsylvania Avenue, NW.,
Washington, DC 20460.
     Hand Delivery: EPA Docket Center, 1301 Constitution Ave.,
NW., EPA West, Room 3334, Washington, DC. Such deliveries are only
accepted during the Docket's normal hours of operation, and special
arrangements should be made for deliveries of boxed information.
    Instructions: Direct your comments to Docket ID No. EPA-HQ-OW-2008-
0553. EPA's policy is that all comments received will be included in
the public docket without change and may be made available online at
http://www.regulations.gov, including any personal information
provided, unless the comment includes information claimed to be
Confidential Business Information (CBI) or other information whose
disclosure is restricted by statute. Do not submit information that you
consider to be CBI or otherwise protected through http://
www.regulations.gov or e-mail. The http://www.regulations.gov Web site
is an ``anonymous access'' system, which means EPA will not know your
identity or contact information unless you provide it in the body of
your comment. If you send an e-mail comment directly to EPA without
going through http://www.regulations.gov your e-mail address will be
automatically captured and included as part of the comment that is
placed in the public docket and made available on the Internet. If you
submit an electronic comment, EPA recommends that you include your name
and other contact information in the body of your comment and with any
disk or CD-ROM you submit. If EPA cannot read your comment due to
technical difficulties and cannot contact you for clarification, EPA
may not be able to consider your comment. Electronic files should avoid
the use of special characters, any form of encryption, and be free of
any defects or viruses. For additional information about EPA's public
docket visit the EPA Docket Center homepage at http://www.epa.gov/
epahome/dockets.htm.
    Docket: All documents in the docket are listed in the http://
www.regulations.gov index. Although listed in the index, some
information is not publicly available, e.g., CBI or other information
whose disclosure is restricted by statute. Certain other material, such
as copyrighted material, will be publicly available only in hard copy.
Publicly available docket materials are available either electronically
in http://www.regulations.gov or in hard copy at the Office of Water
Docket/EPA/DC, 1301 Constitution Ave., NW., EPA West, Room 3334,
Washington, DC. This Docket Facility is open from 8:30 a.m. until 4:30
p.m., EST, Monday through Friday, excluding legal holidays. The
telephone number for the Public Reading Room is<PHONE_NUMBER>, and the
telephone number for the Office of Water is<PHONE_NUMBER>.

FOR FURTHER INFORMATION CONTACT: Heidi L. Bethel, Health and Ecological
Criteria Division (4304T), U.S. EPA, 1200 Pennsylvania Ave., NW.,
Washington, DC 20460;<PHONE_NUMBER><EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION:

I. What Are Water Quality Criteria?

    Water quality criteria are scientifically derived numeric values
that protect aquatic life or human health from the deleterious effects
of pollutants in ambient water.
    Section 304(a)(1) of the Clean Water Act requires EPA to develop
and publish and, from time to time, revise, criteria for water quality
accurately reflecting the latest scientific knowledge. Water quality
criteria developed under section 304(a) are based solely on data and
scientific judgments on the relationship between pollutant
concentrations and environmental and human health effects. Section
304(a) criteria do not reflect consideration of economic impacts or the
technological feasibility of meeting the chemical concentrations in
ambient water.
    Section 304(a) criteria provide guidance to States and authorized
Tribes in adopting water quality standards that ultimately provide a
basis for controlling discharges or releases of pollutants. The
criteria also provide guidance to EPA when promulgating federal
regulations under section 303(c) when such action is necessary. Under
the CWA and its implementing regulations, States and authorized Tribes
are to adopt water quality criteria to protect designated uses (e.g.,
public water supply, recreational use, industrial use). EPA's
recommended human health water quality criteria do not substitute for
the CWA or regulations, nor are they regulations themselves. Thus,
EPA's recommended criteria do not impose legally binding requirements.
States and authorized Tribes have the discretion to adopt, where
appropriate, other scientifically defensible water quality standards
that differ from these recommendations.

II. What Are the Criteria Revisions?

    EPA is today publishing an update of national recommended water
quality criteria (NRWQC) for protecting human health for acrolein and
phenol. These draft revisions are based on EPA's Methodology for
Deriving Ambient Water Quality Criteria for the Protection of Human
Health (2000), EPA-822-B-00-004 (2000 Human Health Methodology). This
methodology describes the Agency's current approach for deriving
national recommended water quality criteria to protect human health.
    The draft revision of these criteria represents a partial update of
the 304(a) criteria as described in both the draft Methodology
revisions and the Federal Register Notice that accompanied the 2000
Human Health Methodology (65 FR 66444; November 3, 2000). EPA believes
that updating a limited number of components for which there are
available data or improved science (i.e., a partial update) is a
reasonable and efficient means of publishing revised 304(a) criteria
more frequently. EPA has also previously described its process for
publishing revised criteria [see National Recommended Water Quality
Criteria; Notice; Republication (63 FR 68354; December 10, 1998 or EPA
822-Z-99-001) and National Recommended Water Quality Criteria; Notice;
Republication; Correction (64 FR 19781; April 22, 1999) or the Federal
Register Notice for the 2000 Methodology]. EPA indicated that when
making minor revisions to existing criteria based on new information
pertaining to individual components of the criteria, it would typically
publish the recalculated criteria directly as the Agency's national
recommended water quality criteria.
    The draft criteria for acrolein and phenol are being updated with
reference dose (RfD) values from EPA's Integrated Risk Information
System (IRIS) (http://www.epa.gov/iris). Because recalculation of these
two criteria results in significant changes, EPA is publishing them in
today's Notice in order to solicit scientific views. However, EPA does
not intend to subject this recalculation to additional peer review
because the IRIS reference doses being updated in this draft partial
criteria update have been previously peer reviewed.

    Tables 1 and 2 below containing the current and updated draft
criteria for acrolein and phenol were prepared to assist reviewers. The
RfD values used to derive the respective criteria values are also
included in Tables 1 and 2 below.

                                  Table 1--Updated Draft Criteria for Acrolein
----------------------------------------------------------------------------------------------------------------
          Acrolein              Current criteria                       Updated draft criteria
----------------------------------------------------------------------------------------------------------------
IRIS RfD....................  0.0156 mg/(kg-d)      0.0005 mg/(kg-d) (published 6/03)
                               (published 1977).    (http://www.epa.gov/ncea/iris/subst/0364.htm).
Water + Organisms...........  190 [mu]g/l.........  6 [mu]g/l
Organisms Only..............  290 [mu]g/l.........  9 [mu]g/l.
----------------------------------------------------------------------------------------------------------------

                                   Table 2--Updated Draft Criteria for Phenol
----------------------------------------------------------------------------------------------------------------
           Phenol               Current criteria                       Updated draft criteria
----------------------------------------------------------------------------------------------------------------
IRIS RfD....................  0.60 mg/(kg-d)        0.30 mg/(kg-d) (published 9/02)
                               (published 2/90).    (http://www.epa.gov/ncea/iris/subst/0088.htm).
Water + Organisms...........  20,700 [mu]g/l......  10,400 [mu]g/l.
Organisms Only..............  1,700,000 [mu]g/l...  857,000 [mu]g/l.
----------------------------------------------------------------------------------------------------------------

    EPA decided to revise the existing criteria based on partially
updated components of the criteria equations in order to increase the
frequency of scientific improvements to the nationally recommended
criteria using acceptable, currently-available information. For a water
quality criterion revision based on a partial update to be considered
acceptable to EPA, a component of the criterion (e.g., the
toxicological risk assessment) should be comprehensive (e.g., a new or
revised reference dose (RfD)) or cancer dose-response assessment, as
opposed to simply a new scaling factor), stand alone, and be based on
new national or local data. The criteria for phenol and acrolein are
being updated with more recent reference doses available from EPA's
Integrated Risk Information System (IRIS). IRIS is an electronic data
base maintained by the EPA that provides chemical-specific risk
information on the relationship between chemical exposures and
estimated human health effects. Risk assessment information contained
in IRIS, except as specifically noted, has been reviewed and agreed
upon by an interdisciplinary group of scientists representing various
Program Offices within the Agency and represents Agency-wide consensus.
Therefore, updated IRIS values reflect the most current Agency science
and should be used by States and Tribes in updating or developing new
human health criteria. The Office of Science and Technology will
publish these partial updates of water quality criteria via their Water
Science Web Site (http://www.epa.gov/waterscience).

IV. What Is the Relationship Between the Water Quality Criteria and
Your State or Tribal Water Quality Standards?

    As part of the water quality standards triennial review process
defined in Section 303(c)(1) of the CWA, the States and authorized
Tribes are responsible for maintaining and revising water quality
standards. Water quality standards consist of designated uses, water
quality criteria to protect those uses, a policy for antidegradation,
and general policies for application and implementation. Section
303(c)(1) requires States and authorized Tribes to review and modify,
if appropriate, their water quality standards at least once every three
years.
    States and authorized Tribes must adopt water quality criteria that
protect designated uses. Protective criteria are based on a sound
scientific rationale and contain sufficient parameters or constituents
to protect the designated uses.
    Consistent with 40 CFR131.21 [see: EPA Review and Approval of State
and Tribal Water Quality Standards (65 FR 24641, April 27, 2000)],
water quality criteria adopted by law or regulation by States and
authorized Tribes prior to May 30, 2000, are in effect for CWA purposes
unless superseded by federal regulations (see, for example, the
National Toxics Rule, 40 CFR 131.36; Water Quality Standards for Idaho,
40 CFR 131.33). New or revised water quality criteria adopted into law
or regulation by States and authorized Tribes on or after May 30, 2000
are in effect for CWA purposes only after EPA approval.

V. What Is the Status of Existing Recommended Criteria While They Are
Under Revision?

    Water quality criteria published by EPA remain the Agency's
recommended water quality criteria until EPA revises or withdraws the
criteria. The current criteria for acrolein and phenol will remain in
effect until EPA publishes the updated criteria.

VI. Where Can I Find More Information About Water Quality Criteria and
Water Quality Standards?

    For more information about water quality criteria and Water Quality
Standards refer to the following: Water Quality Standards Handbook (EPA
823-B94-005a); Advanced Notice of Proposed Rule Making (ANPRM), (63 FR
36742); Water Quality Criteria and Standards Plan--Priorities for the
Future (EPA 822-R-98-003); Guidelines and Methodologies Used in the
Preparation of Health Effects Assessment Chapters of the Consent Decree
Water Criteria Documents (45 FR 79347); Methodology for Deriving
Ambient Water Quality Criteria for the Protection of Human Health
(2000), (EPA-822-B-00-004); Guidelines for Deriving Numerical National
Water Quality Criteria for the Protection of Aquatic Organisms and
Their Uses (EPA 822/R-85-100); National Strategy for the Development of
Regional Nutrient Criteria (EPA 822-R-98-002); and EPA Review and
Approval of State and Tribal Water Quality Standards (65 FR 24641).
    You can find these publications through EPA's National Service
Center for Environmental Publications (NSCEP, previously NCEPI) or on
the Office of Science and Technology's Home-page (http://www.epa.gov/
waterscience).

    Dated: August 28, 2008.
Ephraim S. King,
Director, Office of Science and Technology.
[FR Doc. E8-21460 Filed 9-12-08; 8:45 am]

BILLING CODE 6560-50-P